Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Stocks in this Quantisnow insightHealth Care
Historical context for MDCX
Across the 29 sessions after earlier MDCX headlines, the stock closed higher 13 times and lower 16 times, with a median move of 6.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | MDCX | SPY |
|---|---|---|---|
| Oct 8, 2026 | Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value | -36.4% | -0.4% |
| Sep 29, 2026 | Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer | +3.0% | -0.2% |
| Sep 21, 2026 | Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment | +0.4% | +1.6% |
| Sep 10, 2026 | Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose | -5.3% | -0.6% |
| Sep 8, 2026 | Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company | -1.2% | -0.5% |
| Aug 13, 2026 | Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update | +6.9% | +0.7% |
Keep researching MDCX
Quantisnow market dataNASDAQ
MDCX
Medicus Pharma Ltd.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for MDCX
Full MDCX profile on Quantisnow Follow MDCX and get a push notification the moment its next story breaks.